

**Wright Medical Group, Inc.**  
**Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency**  
(dollars in thousands--unaudited)

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>June 30, 2015</b>		<b>June 30, 2015</b>	
	<b>International</b>	<b>Total</b>	<b>International</b>	<b>Total</b>
	<b>Net Sales</b>	<b>Net Sales</b>	<b>Net Sales</b>	<b>Net Sales</b>
<b>Net sales, as reported</b>	\$ 22,150	\$ 80,420	\$ 42,598	\$ 158,354
Currency impact as compared to prior period	3,005	3,005	5,738	5,738
<b>Net sales, excluding the impact of foreign currency</b>	<b>\$ 25,155</b>	<b>\$ 83,425</b>	<b>\$ 48,336</b>	<b>\$ 164,092</b>

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(in thousands--unaudited)

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>June 30, 2015</b>	<b>June 30, 2014</b>	<b>June 30, 2015</b>	<b>June 30, 2014</b>
<b>Operating Loss</b>				
<b>Operating loss, as reported</b>	\$ (34,342)	\$ (29,171)	\$ (67,463)	\$ (52,217)
<i>Reconciling items impacting Gross Profit:</i>				
Inventory step-up amortization	21	615	49	1,219
Total	21	615	49	1,219
<i>Reconciling items impacting Selling, General and Administrative expense:</i>				
Distributor conversions	—	51	—	156
Due diligence, transaction and transition costs	12,129	5,888	23,153	13,290
Total	12,129	5,939	23,153	13,446
<i>Reconciling items impacting Amortization of Intangible Assets:</i>				
Amortization of distributor non-competes	25	627	49	1,064
<b>Operating loss, as adjusted</b>	<b>\$ (22,167)</b>	<b>\$ (21,990)</b>	<b>\$ (44,212)</b>	<b>\$ (36,488)</b>
<b>Operating loss, as adjusted, as a percentage of net sales</b>	<b>(27.6)%</b>	<b>(30.4)%</b>	<b>(27.9)%</b>	<b>(25.4)%</b>

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(in thousands--unaudited)

	<u>Three Months Ended</u>		<u>Six Months Ended</u>	
	<u>June 30, 2015</u>	<u>June 30, 2014</u>	<u>June 30, 2015</u>	<u>June 30, 2014</u>
<b>EBITDA</b>				
<b>Net loss from continuing operations, as reported</b>	\$ (37,306)	\$ (53,583)	\$ (83,554)	\$ (83,881)
Interest expense, net	10,959	4,172	18,608	8,308
Provision (benefit) for income taxes	158	1,970	324	(10,200)
Depreciation	5,418	4,599	10,698	8,840
Amortization of intangible assets	2,565	2,675	5,179	4,862
<b>EBITDA</b>	<b>(18,206)</b>	<b>(40,167)</b>	<b>(48,745)</b>	<b>(72,071)</b>
<i>Reconciling items impacting EBITDA</i>				
Non-cash stock-based compensation expense	3,344	3,778	5,681	6,098
Other expense, net	(8,153)	18,270	(2,841)	33,556
Inventory step-up amortization	21	615	49	1,219
Distributor conversions	—	51	—	156
Due diligence, transaction and transition costs	12,129	5,888	23,153	13,290
<b>Adjusted EBITDA</b>	<b>\$ (10,865)</b>	<b>\$ (11,565)</b>	<b>\$ (22,703)</b>	<b>\$ (17,752)</b>
<b>Adjusted EBITDA as a percentage of net sales</b>	<b>(13.5)%</b>	<b>(16.0)%</b>	<b>(14.3)%</b>	<b>(12.4)%</b>

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(in thousands, except per share data--unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2015	June 30, 2014	June 30, 2015	June 30, 2014
<b>Net Income</b>				
<b>Loss before taxes, as reported</b>	\$ (37,148)	\$ (51,613)	\$ (83,230)	\$ (94,081)
<i>Pre-tax impact of reconciling items:</i>				
Inventory step-up amortization	21	615	49	1,219
Distributor conversion and non-competes	25	678	49	1,220
Non-cash interest expense on 2017 & 2020 Convertible Notes	6,633	2,295	11,090	4,554
Write-off of unamortized debt discount and deferred financing fees	—	—	25,201	—
Derivatives mark-to-market adjustment	(435)	—	(7,369)	1,000
Due diligence, transaction and transition costs	12,129	5,888	23,153	13,290
CVR mark-to-market adjustments	(8,465)	18,499	(21,919)	32,794
Contingent consideration fair value adjustment	155	—	155	—
<b>Loss before taxes, as adjusted</b>	<b>(27,085)</b>	<b>(23,638)</b>	<b>(52,821)</b>	<b>(40,004)</b>
<b>Provision (benefit) for income taxes, as reported</b>	<b>\$ 158</b>	<b>\$ 1,970</b>	<b>\$ 324</b>	<b>\$ (10,200)</b>
U.S. tax impact resulting from gain in discontinued operations	—	(1,646)	—	10,716
Tax effect of reconciling items	27	—	27	—
<b>Provision (benefit) for income taxes, as adjusted</b>	<b>\$ 185</b>	<b>\$ 324</b>	<b>\$ 351</b>	<b>\$ 516</b>
<b>Effective tax rate, as adjusted</b>	<b>(0.7)%</b>	<b>(1.4)%</b>	<b>(0.7)%</b>	<b>(1.3)%</b>
<b>Net loss from continuing operations, as adjusted</b>	<b>\$ (27,270)</b>	<b>\$ (23,962)</b>	<b>\$ (53,172)</b>	<b>\$ (40,520)</b>
<b>Weighted-average number of shares outstanding-diluted</b>	<b>51,056</b>	<b>49,640</b>	<b>50,963</b>	<b>49,135</b>
<b>Net loss from continuing operations, as adjusted, per diluted share</b>	<b>\$ (0.53)</b>	<b>\$ (0.48)</b>	<b>\$ (1.04)</b>	<b>\$ (0.82)</b>

**Wright Medical Group, Inc.**  
**Reconciliation of Free Cash Flow**  
(dollars in thousands--unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2015	June 30, 2014	June 30, 2015	June 30, 2014
Net cash used in operating activities	\$ (25,754)	\$ (24,350)	\$ (51,000)	\$ (51,590)
Capital expenditures	(13,900)	(16,448)	(25,754)	(24,284)
Free cash flow	<b>\$ (39,654)</b>	<b>\$ (40,798)</b>	<b>\$ (76,754)</b>	<b>\$ (75,874)</b>